Single-nucleotide polymorphisms within TOLLIP and the efficacy of inhaled N-acetylcysteine therapy in idiopathic pulmonary fibrosis.
K. Koyama (Tokushima, Japan), S. Sakamoto (Tokyo, Japan), S. Homma (Tokyo, Japan), S. Sato (Tokushima, Japan), M. Hanibuchi (Tokushima, Japan), Y. Toyoda (Tokushima, Japan), K. Masuda (Okayama, Japan), I. Imoto (Aichi, Japan), T. Isshiki (Tokyo, Japan), S. Miyoshi (Tokyo, Japan), M. Kato (Tokyo, Japan), K. Takahashi (Tokyo, Japan), K. Kataoka (Aichi, Japan), Y. Kondoh (Aichi, Japan), Y. Nishioka (Tokushima, Japan)
Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Koyama (Tokushima, Japan), S. Sakamoto (Tokyo, Japan), S. Homma (Tokyo, Japan), S. Sato (Tokushima, Japan), M. Hanibuchi (Tokushima, Japan), Y. Toyoda (Tokushima, Japan), K. Masuda (Okayama, Japan), I. Imoto (Aichi, Japan), T. Isshiki (Tokyo, Japan), S. Miyoshi (Tokyo, Japan), M. Kato (Tokyo, Japan), K. Takahashi (Tokyo, Japan), K. Kataoka (Aichi, Japan), Y. Kondoh (Aichi, Japan), Y. Nishioka (Tokushima, Japan). Single-nucleotide polymorphisms within TOLLIP and the efficacy of inhaled N-acetylcysteine therapy in idiopathic pulmonary fibrosis.. 2243
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation Source: Eur Respir J, 57 (2) 2003198; 10.1183/13993003.03198-2020 Year: 2021
PECAM-1 single nucleotide polymorphisms and idiopathic pulmonary fibrosis Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011
Polymorphism of the genes of xenobiothics detoxification in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2004; 24: Suppl. 48, 536s Year: 2004
TNF gene polymorphisms and asthma development in cystic fibrosis patients Source: Annual Congress 2010 - Cystic fibrosis: clinical and laboratory studies Year: 2010
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016
Inhalation therapy of interferon-gamma in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 266s Year: 2005
The pharmacogenetic effect of ADRB2 polymorphisms on therapeutic response in COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012
Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019
Anti-fibrotic role of inhaled interferon-γ in idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015
Association of VDR, COL1A1 and CALCR genes polymorphisms with susceptibility to steroid osteoporosis in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010
Cytokines gene polymorphisms (TNFA, LTA, IL1B, IL1RN and IL10) in children with chronic bronchopulmonary disease and cystic fibrosis Source: Eur Respir J 2004; 24: Suppl. 48, 396s Year: 2004
Cryptogenic pulmonary fibrosis and gene polymorphism Source: Annual Congress 2007 - The role of gene polymorphisms in pulmonary disease susceptibility Year: 2007
CTGF and TNFa expression in alveolar macrophages of patients with idiopathic pulmonary fibrosis before and after treatment with azathioprine and interferon-g Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009
MUC5B genotype affects survival of patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019
Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019
Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017
Polymorphism of NRAMP1 gene in chronic obstructive pulmonary disease patients Source: Eur Respir J 2004; 24: Suppl. 48, 315s Year: 2004
Efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2006; 28: Suppl. 50, 767s Year: 2006
Correlation of IL-1 alpha and IL-4 promotor region gene polymorphisms and clinical parameters in idiopathic pulmonary fibrosis Source: Annual Congress 2006 - Systemic diseases, environmental and genetic factors in interstitial lung disease Year: 2006
Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018